T
Thomas D. Schiano
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 432
Citations - 12976
Thomas D. Schiano is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 53, co-authored 394 publications receiving 11023 citations. Previous affiliations of Thomas D. Schiano include University of Chicago & SUNY Downstate Medical Center.
Papers
More filters
Journal ArticleDOI
Evidence-Based Incorporation of Serum Sodium Concentration Into MELD
Scott W. Biggins,W. Ray Kim,Norah A. Terrault,Sammy Saab,Vijay Balan,Thomas D. Schiano,Joanne T. Benson,Terry M. Therneau,Walter K. Kremers,Russell H. Wiesner,Patrick S. Kamath,Goran B. Klintmalm +11 more
TL;DR: An evidence-based method is demonstrated to incorporate Na into MELD, which provides more accurate survival prediction than MELD alone and if used to allocate grafts, would affect 27% of the transplant recipients.
Journal ArticleDOI
Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study
Naga Chalasani,Herbert L. Bonkovsky,Robert J. Fontana,William M. Lee,Andrew Stolz,Jayant A. Talwalkar,K. Rajendar Reddy,Paul B. Watkins,Victor J. Navarro,Huiman X. Barnhart,Jiezhun Gu,Jose Serrano,Jawad Ahmad,Nancy Bach,Meena B. Bansal,Huiman X. Barnhart,Kimberly L. Beavers,Herbert L. Bonkovsky,Francisco O. Calvo,Charissa Y. Chang,Hari S. Conjeevaram,Gregory E. Conner,Jama M. Darling,Ynto S. de Boer,Douglas T. Dieterich,Frank DiPaola,Francisco A. Durazo,James E. Everhart,Robert J. Fontana,Marwan Ghabril,David Goldstein,Vani Gopalreddy,Priya Grewal,Paul H. Hayashi,Jay H. Hoofnagle,Neil Kaplowitz,Suthat Liangpunsakul,Steven N. Lichtman,Lawrence Liu,Victor Navarro,Joseph A. Odin,Simona Rossi,Mark W. Russo,Thomas D. Schiano,Averell H. Sherker,Raj Vuppalanchi,Paul B. Watkins,Steven Zacks,Amanda Balasco,Kristin Chesney,Audrey Corne,Sherrie Cummings,Gale Groseclose,Alex Hammett,Judy Hooker,Varun Kesar,Sophana Mao,Kenari Marks,Regina McFadden,Yolanda Melgoza,Sherif Mikhail,Susan Milstein,Wendy Morlan,Val Peacock,Nidia Rosado,Tracy Russell,Maricruz Vega,Manisha Verma,Patricia F. Walker,Rachana Yalamanchili,Michelle McClanahan-Crowder,Katherine Galan,Tuan Chau,Kowsalya Ragavan,Hoss Rostami,Carmel Puglisi-Scharenbroich,Rebecca Torrance,Rebekah Van Raaphorst +77 more
TL;DR: In this article, the authors present characteristics and subgroup analyses from the first 1257 patients enrolled in the study, and conclude that there are no differences in outcomes of patients with short vs long latency of DILI.
Journal ArticleDOI
2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.
Anthony J. Demetris,Christopher Bellamy,Stefan G. Hubscher,Jacqueline G. O'Leary,Parmjeet Randhawa,Sandy Feng,Desley Neil,Robert B. Colvin,Geoffrey W. McCaughan,John J. Fung,A. Del Bello,Finn P. Reinholt,Hironori Haga,Oyedele Adeyi,A J Czaja,Thomas D. Schiano,Maria Isabel Fiel,Maxwell L. Smith,Mylène Sebagh,R Y Tanigawa,Funda Yilmaz,Graeme J.M. Alexander,L Baiocchi,M Balasubramanian,Ibrahim Batal,Atul K. Bhan,John C. Bucuvalas,Carlos Thadeu Schmidt Cerski,F Charlotte,M. E. de Vera,M ElMonayeri,Paulo Fontes,Emma E. Furth,Annette S. H. Gouw,Sara Hafezi-Bakhtiari,John Hart,E Honsova,Wesam Ismail,Tomoo Itoh,N C Jhala,Urmila Khettry,Goran B. Klintmalm,Stuart J. Knechtle,Takaaki Koshiba,Tomasz Kozlowski,Charles Lassman,Jan Lerut,Josh Levitsky,L Licini,R Liotta,George V. Mazariegos,Marta I. Minervini,Joseph Misdraji,Thalachallour Mohanakumar,Johan Mölne,Imad Nasser,James Neuberger,M O'Neil,O Pappo,L Petrovic,Phillip Ruiz,Ozgul Sagol,A Sanchez Fueyo,Eizaburo Sasatomi,Abraham Shaked,M. Shiller,T Shimizu,Banu Sis,Aurelio Sonzogni,Heather L. Stevenson,Swan N. Thung,Giuseppe Tisone,Athanassios C. Tsamandas,Annika Wernerson,Tong Wu,A. Zeevi,Yoh Zen +76 more
TL;DR: New recommendations for complement component 4d tissue staining and interpretation, staging liver allograft fibrosis, and findings related to immunosuppression minimization are included.
Journal ArticleDOI
One Hundred Nine Living Donor Liver Transplants in Adults and Children: A Single-Center Experience
Charles M. Miller,Gabriel Gondolesi,Sander Florman,Cal S. Matsumoto,Luis Muñoz,Tomoharu Yoshizumi,Tarik Artis,Thomas M. Fishbein,Patricia A. Sheiner,Leona Kim-Schluger,Thomas D. Schiano,Benjamin L. Shneider,Sukru Emre,Myron Schwartz +13 more
TL;DR: Living donor liver transplantation has become an important option for patients and has dramatically changed the approach to patients with liver failure and it is expected that living donor liver transplants will represent more than 50% of the authors' transplants within 3 years.
Journal ArticleDOI
Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
Michael P. Curry,Xavier Forns,Raymond T. Chung,Norah A. Terrault,Robert S. Brown,Jonathan M. Fenkel,Fredric D. Gordon,Jacqueline G. O'Leary,Alexander Kuo,Thomas D. Schiano,Gregory T. Everson,Eugene R. Schiff,Alex S. Befeler,Edward Gane,Sammy Saab,John G. McHutchison,G. Mani Subramanian,William T. Symonds,Jill Denning,Lindsay McNair,Sarah Arterburn,Evguenia S. Svarovskaia,Dilip Moonka,Nezam H. Afdhal +23 more
TL;DR: Administration of sofosbuvir and ribavirin before liver transplantation can prevent post-transplant HCV recurrence, related inversely to the number of consecutive days of undetectable HCV RNA before transplantation.